Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation.
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
18 Sep 2023
18 Sep 2023
Historique:
pmc-release:
18
09
2024
medline:
19
9
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown. We sought to compare different PCI timing strategies in TAVI patients. The REVASC-TAVI registry is an international registry including patients undergoing TAVI with significant, stable coronary artery disease (CAD) at preprocedural workup. In this analysis, patients scheduled to undergo PCI before, after or concomitantly with TAVI were included. The main endpoints were all-cause death and a composite of all-cause death, stroke, myocardial infarction (MI) or rehospitalisation for congestive heart failure (CHF) at 2 years. Outcomes were adjusted using the inverse probability treatment weighting (IPTW) method. A total of 1,603 patients were included. PCI was performed before, after or concomitantly with TAVI in 65.6% (n=1,052), 9.8% (n=157) or 24.6% (n=394), respectively. At 2 years, all-cause death was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (6.8% vs 20.1% vs 20.6%; p<0.001). Likewise, the composite endpoint was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (17.4% vs 30.4% vs 30.0%; p=0.003). Results were confirmed at landmark analyses considering events from 0 to 30 days and from 31 to 720 days. In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown.
AIMS
OBJECTIVE
We sought to compare different PCI timing strategies in TAVI patients.
METHODS
METHODS
The REVASC-TAVI registry is an international registry including patients undergoing TAVI with significant, stable coronary artery disease (CAD) at preprocedural workup. In this analysis, patients scheduled to undergo PCI before, after or concomitantly with TAVI were included. The main endpoints were all-cause death and a composite of all-cause death, stroke, myocardial infarction (MI) or rehospitalisation for congestive heart failure (CHF) at 2 years. Outcomes were adjusted using the inverse probability treatment weighting (IPTW) method.
RESULTS
RESULTS
A total of 1,603 patients were included. PCI was performed before, after or concomitantly with TAVI in 65.6% (n=1,052), 9.8% (n=157) or 24.6% (n=394), respectively. At 2 years, all-cause death was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (6.8% vs 20.1% vs 20.6%; p<0.001). Likewise, the composite endpoint was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (17.4% vs 30.4% vs 30.0%; p=0.003). Results were confirmed at landmark analyses considering events from 0 to 30 days and from 31 to 720 days.
CONCLUSIONS
CONCLUSIONS
In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials.
Identifiants
pubmed: 37436190
pii: EIJ-D-23-00186
doi: 10.4244/EIJ-D-23-00186
pmc: PMC10495747
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-599Références
Circ Cardiovasc Interv. 2022 Dec;15(12):e012417
pubmed: 36538579
N Engl J Med. 2020 Oct 8;383(15):1447-1457
pubmed: 32865376
Circ Cardiovasc Interv. 2022 Feb;15(2):e011045
pubmed: 35167332
Circ Cardiovasc Interv. 2016 Nov;9(11):
pubmed: 27803040
EuroIntervention. 2022 Feb 04;17(14):e1126-e1196
pubmed: 34931612
JACC Cardiovasc Interv. 2021 Sep 27;14(18):1965-1974
pubmed: 34556269
Am J Cardiol. 2020 May 1;125(9):1361-1368
pubmed: 32106928
Catheter Cardiovasc Interv. 2021 Feb 15;97(3):529-539
pubmed: 32845036
Am J Cardiol. 2001 May 15;87(10):1216-7; A7
pubmed: 11356405
Eur J Cardiothorac Surg. 2012 Nov;42(5):S45-60
pubmed: 23026738
Int J Cardiol. 2022 Oct 15;365:114-122
pubmed: 35870638
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
JACC Cardiovasc Interv. 2021 Jul 26;14(14):1578-1590
pubmed: 34294400
JACC Cardiovasc Interv. 2020 Nov 9;13(21):2542-2555
pubmed: 33069648
Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):456-457
pubmed: 34949549
EuroIntervention. 2023 May 15;19(1):37-52
pubmed: 36811935
JACC Cardiovasc Interv. 2020 May 11;13(9):1030-1042
pubmed: 32192985
Circ Cardiovasc Interv. 2019 Dec;12(12):e008263
pubmed: 31752515
JACC Cardiovasc Interv. 2021 Oct 11;14(19):2097-2108
pubmed: 34538602
EuroIntervention. 2022 Aug 19;18(6):503-513
pubmed: 35450838
J Am Coll Cardiol. 2022 Jan 18;79(2):197-215
pubmed: 34895951
J Am Heart Assoc. 2020 Mar 3;9(5):e015133
pubmed: 32102615
EuroIntervention. 2018 Jan 20;13(13):1512-1519
pubmed: 28846545